Metastatic Cancer — Advanced Stage Malignancy

Metastatic cancer describes a malignant condition where secondary tumours have formed in organs distant from the original tumour site. Clinically staged as stage IV, this diagnosis indicates that cancer cells have established self-sustaining colonies within other physiological systems. Despite spreading to new organs, the cancer is always classified and treated according to the tissue of origin because the cells retain their primary histological and genetic profile.

Historically associated with very limited survival horizons, the modern landscape of metastatic cancer has evolved substantially. Due to developments in targeted oncology and immunomodulatory drugs, some metastatic cancers can be controlled for extended intervals. Management focuses on treating the disease systemically, suppressing disease progression, mitigating cancer-related symptoms, and maintaining functional autonomy and emotional wellbeing for as long as possible.

A diagnosis of metastatic cancer reframes the clinical approach from localised curative intervention to comprehensive disease control and symptom management. Understanding this diagnosis helps patients collaborate with their oncology team to select treatments that align with their personal values, lifestyle priorities, and tolerance for side effects. It prompts crucial discussions regarding clinical trial opportunities, palliative and supportive care integration, and emotional wellbeing. By actively engaging in these discussions, patients can make informed choices about treatment sequences, monitoring schedules, and maintaining their day-to-day quality of life.

Staging workups for metastatic cancer involve comprehensive diagnostic imaging, including PET-CT scans, abdominal and pelvic CTs, and brain MRI scans. A biopsy of a metastatic site is often performed to confirm histological concordance with the primary tumour and to detect newly acquired genetic alterations. Testing regularly incorporates next-generation sequencing, microsatellite instability (MSI) testing, and specific biomarker assays (such as HER2, EGFR, ALK, or PD-L1). Serial blood tests, including complete blood counts and tumour markers, monitor response to ongoing systemic treatment.

Any invasive cancer can become metastatic, but it is most frequently diagnosed in prevalent solid tumours such as lung cancer, breast cancer, colorectal cancer, prostate cancer, and melanoma. In some cases, metastatic cancer presents without an identifiable initial site; this clinical scenario is termed cancer of unknown primary (CUP). Common anatomical sites for secondary tumour deposition across these cancer types include the regional and distant lymph nodes, liver, lungs, skeletal system, and central nervous system.

Treating metastatic cancer primarily relies on whole-body therapies, including chemotherapy, targeted small-molecule inhibitors, immunotherapy, and hormone therapy. The specific therapeutic sequence depends on the tumour's molecular markers, previous therapies, and patient performance status. Targeted radiation or surgical interventions may be employed selectively for oligometastatic lesions or to alleviate focal symptoms like bone pain. Palliative care is routinely incorporated from the time of diagnosis to manage pain, nausea, and fatigue, working alongside anti-cancer therapies to maintain overall wellbeing.